Pharvaris says phase 3 RAPIDe-3 trial shows oral deucrictibant speeds symptom relief in HAE attacks
PHVS•Pharvaris said its phase 3 RAPIDe-3 trial found oral deucrictibant shortened time to symptom relief and full resolution of hereditary angioedema attacks versus placebo. Regulators are reviewing the U.S. NDA and EU MAA for on-demand use, with an FDA target date of April 23, 2027.
1. Trial results and review
Pharvaris reported phase 3 RAPIDe-3 results for oral deucrictibant, which were published in The Lancet. Most attacks were controlled with one dose; the treatment was described as well tolerated, with no new safety signals reported. Regulators are reviewing the U.S. NDA and EU MAA for on-demand use, and the FDA’s PDUFA target date is April 23, 2027.
